Measurements of Ξ(1530)0{\Xi \left( 1530\right) ^{0}} and Ξ‾(1530)0{\overline{\Xi }\left( 1530\right) ^{0}} production in proton–proton interactions at sNN\sqrt{s_{NN}} = 17.3 = 17.3 GeV \text{ GeV } in the NA61/SHINE experiment

Double-differential yields of $\Xi\left(1530\right)^{0}$ and $\overline{\Xi}\left(1530\right)^{0}$ resonances produced in \pp interactions were measured at a laboratory beam momentum of 158~\GeVc. This measurement is the first of its kind in \pp interactions below LHC energies. It was performed at the CERN SPS by the \NASixtyOne collaboration. Double-differential distributions in rapidity and transverse momentum were obtained from a sample of 26$\cdot$10$^6$ inelastic events. The spectra are extrapolated to full phase space resulting in mean multiplicity of $\Xi\left(1530\right)^{0}$ (6.73 $\pm$ 0.25 $\pm$ 0.67)$\times10^{-4}$ and $\overline{\Xi}\left(1530\right)^{0}$ (2.71 $\pm$ 0.18 $\pm$ 0.18)$\times10^{-4}$. The rapidity and transverse momentum spectra and mean multiplicities were compared to predictions of string-hadronic and statistical model calculations

Measurements of Ξ−{\Xi }{^-} and Ξ‾+\overline{\Xi }{^+} production in proton–proton interactions at sNN\sqrt{s_{NN}}=17.3 GeV = 17.3 GeV in the NA61/SHINE experiment

International audienceThe production of $\Xi (1321)^{-}$ and $\overline{\Xi }(1321)^{+}$ hyperons in inelastic p+p interactions is studied in a fixed target experiment at a beam momentum of 158 $\hbox {Ge}\hbox {V}\!/\!c$. Double differential distributions in rapidity ${y}$ and transverse momentum $p_{T}$ are obtained from a sample of 33M inelastic events. They allow to extrapolate the spectra to full phase space and to determine the mean multiplicity of both ${\Xi }{^-}$ and $\overline{\Xi }{^+}$. The rapidity and transverse momentum spectra are compared to transport model predictions. The ${\Xi }{^-}$ mean multiplicity in inelastic p+p interactions at 158 $\hbox {Ge}\hbox {V}\!/\!c$ is used to quantify the strangeness enhancement in A+A collisions at the same centre-of-mass energy per nucleon pair

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p<0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p<0·0001). Interpretation: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Comparative study on growth and yield performance of oyster mushroom (Pleurotus florida) on different substrates

Experiment was carried out in the mushroom cultivation laboratory, Horticulture Center, Khairtala, Jessore to evaluate the better performance of oyster mushroom Pleurotus florida in different substrate compositions as well as to find out the better substrate for mushroom cultivation. Highest mycelium running rate was found in banana leaves and rice straw (1:1) but the lowest in control. Completion of mycelium running time was lowest in banana leaves and rice straw (1:3 and 3:1). Number of total primordia and effective primordia, found highest in control but the maximum pileus thickness was measured from rice straw. Highest biological yield and economic yield (164.4 g and 151.1 g) was obtained from rice straw which was much higher than control. From the graphical view, both positive and negative relationships were found between economic yield and different yield contributing attributes

Measurements of multiplicity fluctuations of identified hadrons in inelastic proton–proton interactions at the CERN Super Proton Synchrotron

Measurements of multiplicity fluctuations of identified hadrons produced in inelastic p+p interactions at 31, 40, 80, and 158 GeV/c beam momentum are presented. Three different measures of multiplicity fluctuations are used: the scaled variance ω and strongly intensive measures Σ and Δ. These fluctuation measures involve second and first moments of joint multiplicity distributions. Data analysis is preformed using the Identity method which corrects for incomplete particle identification. Strongly intensive quantities are calculated in order to allow for a direct comparison to corresponding results on nucleus–nucleus collisions. The results for different hadron types are shown as a function of collision energy. A comparison with predictions of string-resonance Monte-Carlo models: EPOS, SMASH and VENUS, is also presented